A Smart + Strong Site
Subscribe to:
Newsletters
POZ magazine
JOIN AIDSMEDS YouTube

Back to home » Treatment News » Top Stories

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
FDA Approves New Single-Tablet HIV Regimen, Triumeq
Life Expectancy for Young People With HIV Is Nearly Normal
A 15-Year Jump in Life Expectancy for People With HIV
Scientists Devise Method of Snipping HIV From Immune Cells
Monkey HIV Vaccine Success Opens Door for Human Trials
HIV Combo Pill Less Toxic Thanks to New Form of Tenofovir
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


emailprint

March 21, 2012

Transmitted HIV Drug Resistance on the Rise in U.S.

by Tim Horn

CROI 2012 New surveillance data from the U.S. Centers for Disease Control and Prevention (CDC) suggest that about two in 10 individuals infected with HIV in recent years involved strains of the virus harboring mutations conferring at least partial resistance to one ore more available antiretroviral (ARV). The report was presented Wednesday, March 7, at the 19th Conference on Retroviruses and Opportunistic Infections in Seattle.

The U.S. Variant, Atypical, and Resistant HIV Surveillance (VARHS) system, in which HIV specimens from newly diagnosed individuals are tested for drug-resistance mutations, was established by the CDC to provide the clearest picture to date of the scope and type of resistance in the United States.

The analysis reported at CROI included a total of 10,338 resistance profiles from eight U.S. regions; this consisted of 2,339 profiles from individuals with recent infections (confirmed using a specialized antibody test or a negative HIV test results within six months before diagnosis) and 7,999 profiles from individuals with confirmed long-standing HIV infection (individuals diagnosed with AIDS within six months of testing positive for the virus). Regions represented in the analysis were Seattle, Los Angeles, Chicago, Colorado, Michigan, Louisiana, New York and South Carolina.

The system uses standard genotypic resistance testing, which identifies specific viral mutations associated with drug resistance. Because neither the recently infected individuals nor the subjects with established infection included in the analysis had yet started treatment, the presence of any HIV drug resistance mutations in their blood would indicate that the resistant virus was transmitted to them at the time of their infection.

Overall, 15.2 percent of all samples included in the analysis had evidence of at least one transmitted drug resistance mutation.

Among the recently infected individuals, 19.1 percent had evidence of at least partial resistance to at least one drug in a particular ARV class, compared with 14.7 percent of the individuals with long-standing HIV infection. This difference was found to be statistically significant, meaning it was too great to have occurred by chance.

Resistance to drugs in just one class was documented in 15.4 percent of recently infected individuals, compared with 12.5 percent of those with established infections. This difference between the two groups was statistically significant.

Resistance to drugs in two ARV classes was documented in 3.1 percent of those newly infected with HIV, compared with 1.7 percent of those with established infection. Here too the difference was statistically significant.

Rates of resistance to drugs in three classes were similar in the two groups: 0.6 percent.

HIV resistance to nucleoside reverse transcriptase inhibitors was somewhat more common among those with recent infection—7.6 percent versus 6.7 percent—though this difference was not statistically significant. The same held for resistance to protease inhibitors, found in 4.6 percent of those with recent infections and 4 percent of those with established infections.

Where there was a statistically significant difference was in the prevalence rates of HIV strains at least partially resistant to non-nucleoside reverse transcriptase inhibitors (NNRTIs). According to the presented data, 11.1 percent of the recent infection samples had mutations conferring NNRTI resistance, compared with 6.9 percent of the samples from those with established infections.

The report also noted statistically significant increases in key ARV mutations between 2006 and 2009 among recently infected individuals. Between these years, HIV strains with evidence of at least partial resistance to drugs in at least one ARV class increased by more than 5 percent annually. As for specific drug classes, the only statistically significant annual increase was for the NNRTI class—the prevalence of NNRTI mutations among recently infected individuals increased by more than 6 percent a year.

“In this analysis,” the authors concluded, “one in six newly diagnosed HIV infections contained one or more mutations associated with transmitted antiretroviral drug resistance,” adding that “the increasing trend in the prevalence of NNRTI [transmitted drug-resistance mutations] may adversely impact the use of population and effective NNRTI-based HIV treatment regimens.”

The researchers also reiterated that the prevalence of these mutations was 1.3 times higher among those with recent infection compared with those recently diagnosed with long-standing infections. However, they warned, a strict comparison between the two groups may not be entirely accurate, as transmitted strains of HIV with drug resistance mutations can be driven to undetectable levels and largely replaced by virus that appears to be drug sensitive in individuals with long-standing established infection.

Search: antiretroviral, drug, resistance, genotype, mutations, tansmission, varhs, cdc, croi, 2012


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (1 total)


[Go to top]

Quick Links
About HIV and AIDS
The Cure
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Disclosure
Lipodystrophy
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Blogs
Conference Coverage
Health Services Directory
POZ Magazine


    acousticmat
    Tucson
    Arizona


    Loveladyd
    Washington
    DC


    sefarady
    New York
    California


    albsur7436
    San Francisco
    California
Click here to join POZ Personals!
Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014


21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014


7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013


more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.